Financial Gravity Asset Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Financial Gravity Asset Management’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Hold	23	–	–	﹤0.01%	989
2025 Q4	$0	Hold	23	–	–	﹤0.01%	967
2025 Q3	$0	Buy	+23	New	–	﹤0.01%	979
2025 Q1	$0	Buy	+23	New	–	﹤0.01%	1062
2024 Q2	$0	Buy	61 +1	+2%	–	﹤0.01%	1849
2024 Q1	$0	Hold	60	–	–	﹤0.01%	1352
2023 Q4	$0	Buy	+60	New	–	﹤0.01%	1357
2021 Q3	$6K	Hold	123	–	–	﹤0.01%	924
2021 Q2	$6K	Buy	+123	New	+$6K	﹤0.01%	947
2020 Q4	$1K	Buy	+123	New	+$1K	﹤0.01%	469
2019 Q4	$6K	Buy	184 +1	+0.5%	+$33	﹤0.01%	1259
2019 Q3	$1K	Hold	183	–	–	﹤0.01%	1168
2019 Q2	$1K	Sell	183 -2	-1%	-$11	﹤0.01%	1197
2019 Q1	$1K	Buy	+185	New	+$1.22K	﹤0.01%	1297
2018 Q3	$4K	Buy	561 +101	+22%	+$729	﹤0.01%	828
2018 Q2	$3K	Buy	460 +325	+241%	+$2.56K	﹤0.01%	941
2018 Q1	$1K	Buy	+135	New	+$1.11K	﹤0.01%	1373

Other funds holding SVA

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Financial Gravity Asset Management's SVA Position: Q1 2026 in Review

Financial Gravity Asset Management held its Sinovac Biotech, Ltd (SVA) position steady in Q1 2026 at 23 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #989.

Financial Gravity Asset Management first reported a position in SVA in Q1 2018 and has held it in 17 quarters since. The position peaked at $6K in Q3 2021. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

Financial Gravity Asset Management held 23 shares of Sinovac Biotech, Ltd worth $0 as of Q1 2026.
Financial Gravity Asset Management left its Sinovac Biotech, Ltd share count unchanged in Q1 2026.
Sinovac Biotech, Ltd made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q1 2026, its #989 holding.
Financial Gravity Asset Management first reported a position in Sinovac Biotech, Ltd in Q1 2018 and has held it in 17 quarters since.
Financial Gravity Asset Management's Sinovac Biotech, Ltd position peaked at $6K in Q3 2021.
28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Financial Gravity Asset Management's 13F filing for Q1 2026, filed 8 May 2026.